# Ruxolitinib for Treatment of Covid-19 Induced Lung Injury ARDS

> **NCT04359290** · PHASE2 · COMPLETED · sponsor: **Philipps University Marburg** · enrollment: 15 (actual)

## Conditions studied

- ARDS, Human
- COVID

## Interventions

- **DRUG:** Ruxolitinib administration

## Key facts

- **NCT ID:** NCT04359290
- **Lead sponsor:** Philipps University Marburg
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-01
- **Primary completion:** 2020-12-31
- **Final completion:** 2021-07-30
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2021-08-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04359290

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04359290, "Ruxolitinib for Treatment of Covid-19 Induced Lung Injury ARDS". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04359290. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*